argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
23 sep 2015 - 07:15
Statutaire naam
argenx SE
Titel
arGEN-X' Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody(TM) Against IL-6
Bericht
Breda, the Netherlands / Ghent, Belgium, 23 September - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today reports that its partner RuiYi, Inc., a company focused on the discovery and development of novel biologic therapies, has announced the first human dosing of Gerilimzumab, a novel monoclonal antibody neutralizing the IL-6 cytokine, for the treatment of autoimmune disorders including rheumatoid arthritis.
Gerelateerde downloads
Datum laatste update: 01 september 2024